Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.

Luetkemeyer, Anne F

Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. [electronic resource] - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Jun 2015 - 1860-3 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

1537-6591

10.1093/cid/civ155 doi


Alkynes
Antitubercular Agents--blood
Arylamine N-Acetyltransferase--genetics
Benzoxazines--blood
Cyclopropanes
Cytochrome P-450 CYP2B6--genetics
Female
Genotype
HIV Infections--complications
Humans
Male
Peru
Pharmacogenetics
Rifampin--therapeutic use
South Africa
Tuberculosis--complications
Uganda